Paradigm Biocapital Advisors LP Olema Pharmaceuticals, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.62 Billion
- Q4 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 7,304,970 shares of OLMA stock, worth $36.5 Million. This represents 1.62% of its overall portfolio holdings.
Number of Shares
7,304,970
Previous 5,503,600
32.73%
Holding current value
$36.5 Million
Previous $65.7 Million
35.19%
% of portfolio
1.62%
Previous 2.37%
Shares
6 transactions
Others Institutions Holding OLMA
# of Institutions
161Shares Held
69.2MCall Options Held
235KPut Options Held
1.3K-
Bain Capital Life Sciences Investors, LLC Boston, MA7.47MShares$37.3 Million11.76% of portfolio
-
Bvf Inc San Francisco, CA5.72MShares$28.5 Million1.25% of portfolio
-
Black Rock Inc. New York, NY4MShares$20 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.67MShares$18.3 Million0.05% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.44MShares$17.2 Million0.88% of portfolio
About Olema Pharmaceuticals, Inc.
- Ticker OLMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,419,600
- Market Cap $202M
- Description
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...